The first products in the new procedure are lamivudine GSK 150 mg film-coated tablets and lamivudine / zidovudine infected GSK tablets of Glaxo Group Limited, both as part of of an antiretroviral combination therapy for the treatment of human immunodeficiency virus determined children and adults.
The brightness and stability cerFP505 are similar to other fluorescent proteins used in biomedical research. The fluorescence can be switched on and off, alternating blue and near-UV light. These features make cerFP505 an ideal structure for the development of marker proteins for super – high-resolution microscopy, the researchers say.Is known Taiho Pharmaceutical Co. And its parent company, Otsuka Holdings Co. Were that the Committee of for Human Medicinal , a division of European Medicines Agency , a novel oral anti-cancer agent, intended issued for the treatment of advanced stomach cancer adults Krebs has been in combination with cisplatin. The EESC will now recommend that the Commission. granting of approval to market Teysuno, a choice that is usually issued within 67 days off assumption of a opinion by the CHMP ‘We are delighted the CHMP favorable opinion on Teysuno This represents an important step toward a new treatment option adult European life with cancer of the stomach,’said Toru Usami, Chairman, Taiho Pharmaceutical Co.
Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates by the incidence of and mortality Europe in 2006. Ann Oncol 2007; 18:581 – 592.